Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Carbonic anhydrase 2-derived drug-responsive domain regulates membrane-bound cytokine expression and function in engineered T cells.
Inniss MC, Smith SG, Li DJ, Primack B, Sun D, Olinger GY, Sheahan KL, Ross T, Langley M, Young V, Alvarado A, Davoodi S, Geng J, Schebesta M, Ols ML, Tchaicha J, Ter Meulen J, Sethi DK. Inniss MC, et al. Among authors: ter meulen j. Commun Biol. 2025 Jan 9;8(1):28. doi: 10.1038/s42003-024-07410-z. Commun Biol. 2025. PMID: 39789216 Free PMC article.
Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma: A Phase 1 Nonrandomized Controlled Trial.
Seo YD, Lu H, Black G, Smythe K, Yu Y, Hsu C, Ng J, Hermida de Viveiros P, Warren EH, Schroeder BA, O'Malley RB, Cranmer LD, Loggers ET, Wagner MJ, Bonham L, Pillarisetty VG, Kane G, Berglund P, Hsu FJ, Mi X, Alexiev BA, Pierce RH, Riddell SR, Jones RL, Ter Meulen J, Kim EY, Pollack SM. Seo YD, et al. Among authors: ter meulen j. JAMA Oncol. 2023 Dec 1;9(12):1660-1668. doi: 10.1001/jamaoncol.2023.4015. JAMA Oncol. 2023. PMID: 37824131 Free PMC article. Clinical Trial.
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice.
Horvath D, Temperton N, Mayora-Neto M, Da Costa K, Cantoni D, Horlacher R, Günther A, Brosig A, Morath J, Jakobs B, Groettrup M, Hoschuetzky H, Rohayem J, Ter Meulen J. Horvath D, et al. Among authors: ter meulen j. Sci Rep. 2023 Mar 21;13(1):4648. doi: 10.1038/s41598-023-31198-3. Sci Rep. 2023. PMID: 36944687 Free PMC article.
Fabrication of High Aspect Ratio Micro-Structures with Superhydrophobic and Oleophobic Properties by Using Large-Area Roll-to-Plate Nanoimprint Lithography.
Atthi N, Dielen M, Sripumkhai W, Pattamang P, Meananeatra R, Saengdee P, Thongsook O, Ranron N, Pankong K, Uahchinkul W, Supadech J, Klunngien N, Jeamsaksiri W, Veldhuizen P, Ter Meulen JM. Atthi N, et al. Among authors: ter meulen jm. Nanomaterials (Basel). 2021 Jan 29;11(2):339. doi: 10.3390/nano11020339. Nanomaterials (Basel). 2021. PMID: 33572813 Free PMC article.
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1.
Somaiah N, Chawla SP, Block MS, Morris JC, Do K, Kim JW, Druta M, Sankhala KK, Hwu P, Jones RL, Gnjatic S, Kim-Schulze S, Tuballes K, Yishak M, Lu H, Yakovich A, Ter Meulen J, Chen M, Kenney RT, Bohac C, Pollack SM. Somaiah N, et al. Among authors: ter meulen j. Oncoimmunology. 2020 Nov 19;9(1):1847846. doi: 10.1080/2162402X.2020.1847846. Oncoimmunology. 2020. PMID: 33312760 Free PMC article. Clinical Trial.
119 results